The renal tubular acidoses (RTA) are disorders of renal acid-base handling causing a normal-anion-gap (hyperchloremic) metabolic acidosis. Distal RTA (dRTA), the most clinically significant form, is often genetic, autoimmune (as in Sjögren's disease), or drug-induced, and can cause hypokalemia, nephrolithiasis, nephrocalcinosis, bone disease, and — in children — growth failure.
Alkali therapy and a better-tolerated formulation
Oral alkali supplementation (potassium, sodium, or magnesium citrate or bicarbonate) is the mainstay, correcting acidosis and preventing complications; potassium repletion is usually needed in dRTA. Adherence is limited by GI intolerance and frequent dosing. The main therapeutic advance is ADV7103 (Sibnayal), an extended-release combination of potassium citrate and potassium bicarbonate approved in Europe for dRTA, which offers twice-daily dosing with improved tolerability and metabolic control and is supported by Phase 3 data.
A cautionary note on veverimer
Veverimer, a non-absorbed gastrointestinal acid binder once hoped to treat CKD-associated metabolic acidosis, should be viewed with realism: its pivotal VALOR-CKD trial did not slow CKD progression (with only about a 1 mEq/L bicarbonate separation from placebo), and its development did not move forward. It is not an established therapy for RTA or acidosis.
Genetics and special situations
Next-generation sequencing is increasingly used to identify hereditary forms of dRTA and personalize management. Drug-induced RTA usually resolves on withdrawing the offending agent; autoimmune-associated dRTA (e.g., in Sjögren's disease) may require treating the underlying condition, with vigilance for rare but serious complications such as hypokalemic paralysis.
| Approach | Indication | Note |
|---|---|---|
| Alkali therapy | All RTA | Mainstay; adherence-limited |
| ADV7103 (Sibnayal) | Distal RTA | Extended-release; EU-approved |
| Potassium repletion | dRTA with hypokalemia | Prevents paralysis/arrhythmia |
| Genetic testing (NGS) | Hereditary dRTA | Guides diagnosis/management |
Further reading: primary distal RTA management (Medina et al., CJASN 2024); ERKNet/ESPN dRTA clinical practice points; VALOR-CKD veverimer (Tangri et al., JASN 2024, negative trial).